Pharmaceutical Industry on Alert as Generic Drug Reimbursement Rate Set at 45%
Heightened Tension Across the Industry as Drug Price Cuts Become a Reality
Limited Means to Defend Profitability: "Cost Reduction Unavoidable"
Direct Hit to Small and Medium-Sized Pharma Firms... Signals of Restructuring
Concerns Over Weake
"In a system where drug prices continue to decline, cost reduction is virtually the only viable response. In the long term, business diversification and improvements in cost structure will need to happen simultaneously to secure the capacity for research and development (R&D) investment." (Business strategy executive at a major pharmaceutical company)
"R&D is a critical area that determines the future of a company, so it's not something that can be easily reduced. However, as the drug pricing environment deteriorates, the overall capacity for investment inevitably decreases. Ultimately, a recurring pattern will emerge where investments in other areas are cut to protect R&D." (R&D strategy manager at a major pharmaceutical company)
An image showing products being manufactured in a pharmaceutical factory. Getty Images Bank
View original imageTension is spreading throughout the pharmaceutical industry as the reimbursement rate for generic drugs has been set at 45%, falling short of the industry's demand for the upper 40% range. The consensus that cost reduction is unavoidable is rapidly spreading among companies, regardless of whether they are small, mid-sized, or large pharmaceutical firms.
According to the pharmaceutical and bio industry on March 26, following the decision on the generic drug pricing standard by the Health Insurance Policy Review Committee that day, each pharmaceutical company has begun reorganizing its management strategies. This reflects the recognition that, with the downward trend in drug prices maintained, there are limited means to defend profitability.
Under the new plan, the reimbursement rate is set at 45%, but innovative pharmaceutical companies will be eligible for a special rate of 49% for up to four years, while newly introduced quasi-innovative pharmaceutical companies will receive 47% for three years. However, industry insiders believe that the actual compensatory effect of these measures will be limited.
Even large pharmaceutical companies with a diverse pipeline beyond generics are not optimistic about the situation. A company representative stated, "Although the government did listen to industry opinions, ultimately the downward trend in drug prices was maintained," and added, "After the system is implemented, we will have no choice but to monitor its impact across the industry and respond accordingly." Another company official commented, "The impact of this policy will not be limited to a specific area, but will affect the overall cost structure."
Companies' responses are converging on restructuring their cost structures. Company A is reviewing sourcing alternative raw materials and diversifying its supply chains to mitigate the cost burden caused by lower drug prices. The company is also considering reorganizing its business portfolio to focus on higher-profit sectors. Company B has adjusted its investment strategy: while core R&D activities such as new drug development are being maintained, spending in non-core areas such as marketing, facilities, and operations will be managed conservatively across the board.
Among smaller pharmaceutical companies, there are concerns that the latest drug price reform could become a matter of survival. One company representative said, "Large companies have some room to respond by eliminating low-profit items or cutting costs, but the situation is different for smaller firms. The higher a company's dependence on generics, the greater the impact will be." It is reported that some companies are even considering discontinuing low-profit products and improving organizational efficiency.
In particular, for many small pharmaceutical companies whose sales structure relies heavily on Contract Sales Organizations (CSOs) for drug promotion, there is a possibility that the burden will spread externally. An industry insider expressed concern, "If pharmaceutical companies continue to cut costs, the impact could ripple through to the CSO sector as well."
On the 10th, an emergency press conference of the Emergency Committee for Reforming the Drug Pricing System for the Development of the Pharmaceutical and Bio Industry was held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. Photo by Minjae Kwak
View original imageThere is also analysis that a similar tightening trend to that seen during previous large-scale drug price reductions will reemerge. However, since the proportion of R&D investment is now much higher, many believe the impact will be even greater.
Experts believe that this adjustment to the reimbursement rate will place a significant burden on the industry in the short term, as it could weaken the reinvestment structure of R&D based on profits from generic drugs.
Seungkyu Lee, Vice Chairman of the Korea Biotechnology Industry Organization, stated, "With profit margins from generics already not being high, a further reduction in prices will inevitably weaken the momentum for R&D investment in new drug development. As mid-sized pharmaceutical companies are highly dependent on marketing, the shock to the entire ecosystem will be unavoidable." He added, "If external factors are introduced on top of a supply structure that relies on India and China for active pharmaceutical ingredients (APIs), the burden on the industry could grow even larger."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Vice Chairman Lee further noted, "However, if supplementary measures such as incentives for innovative companies are carefully designed, this change in the system could become an opportunity for structural transformation of the industry. With global interest in Korea's pharmaceutical and bio industry at a peak, now may in fact be the last real chance to seize the momentum."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.